Oncology Medical News about Neoplasms Pain Administration, Cutaneous Fentanyl

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

The Use of Transdermal Fentanyl in Cancer Pain: A Compliance Study of Outpatients in Taiwan
American Journal of Hospice and Palliative Medicine, 10/05/09

Chiou T–J et al. – From 2005 to 2006, 822 outpatients received TTS–F to collect pain assessment forms and diaries for 4 weeks. Most (78.7%) patients were initially prescribed 25 microg/h TTS–F. Doses were adjusted weekly at clinicians' discretion, according to pain assessment and side effects. Patients receiving 50 microgg/h, 75 microgg/h, and > 75 microgg/h TTS–F had increased from 17.5% to 32.1%, 1.8% to 3.4%, and 1.9% to 2.2%, respectively, by week 2; further small increases were found in weeks 3 and 4. Pain palliation improved from 60.6% during week 1 to 78.6% at week 4. The common adverse effects were nausea/vomiting. Patient’s compliance was >90%. This study found that the TTS–F is effective and well tolerated.

Exclusive Author Commentary
Tzeon-Jye Chiou, 10/05/09

This is the first article to describe the use of TTS-F in the treatment of pain in advanced cancer patients in Taiwan. It is a valuable article to describe the use of TTS-F as a fist step or second step to treat cancer pain in advanced cancer patients. The result just shows us that the early use of TTS-F in cancer pain is worthful for cancer pain and results in lower incidence of opioid related toxicity.

<< Previous
131-Iodine Tositumomab in lymphoma

Next >>
Choosing the best treatment strategy for chronic myeloid leukemia...